Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Prokidney Corp. (NASDAQ:PROK) Chief Regulatory Officer Darin J. Weber, sold 103,480 shares of Class A Common Stock on July 8, 2025, for $3.02, totaling $312,509. The stock, currently trading at $4.34, has seen remarkable gains with a 544% surge in the past week. According to InvestingPro analysis, the company’s market capitalization stands at $1.09 billion, with technical indicators suggesting overbought conditions.
The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on January 15, 2025. Following the transaction, Weber directly owns zero shares of Prokidney Corp. Want deeper insights into insider trading patterns and 14 additional ProTips? Discover more with InvestingPro.
In other recent news, ProKidney Corp. has reported positive topline results from its Phase 2 REGEN-007 trial, focusing on rilparencel for patients with diabetes and chronic kidney disease. This announcement led to a significant surge in ProKidney’s stock, with Citi analysts raising their price target from $6 to $9, citing the trial’s better-than-expected outcomes. The trial demonstrated statistically significant efficacy in stabilizing the estimated glomerular filtration rate (eGFR) slope in Group 1 patients, which may support accelerated approval in Phase 3 pending FDA confirmation. Despite this positive reception, BofA Securities has maintained its Underperform rating on ProKidney, expressing concerns over trial risks and regulatory uncertainties. The firm cited the absence of a sham comparator in the study and limited data supporting the treatment’s effectiveness. BofA Securities also pointed out the potential for the end-market to remain niche without compelling data. ProKidney plans to present full results at the American Society of Nephrology conference and is preparing for an FDA meeting to discuss eGFR slope as a surrogate endpoint. No serious adverse events related to rilparencel were observed in the trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.